Detalles de la búsqueda
1.
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
Am J Respir Crit Care Med
; 209(2): 137-152, 2024 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37772985
2.
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.
Rheumatology (Oxford)
; 2024 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38460548
3.
Prognostic significance of pericardial effusion in systemic sclerosis-associated pulmonary hypertension: analysis from the PHAROS Registry.
Rheumatology (Oxford)
; 2023 Jul 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37478347
4.
A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
Rheumatology (Oxford)
; 62(4): 1543-1551, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36031807
5.
Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort.
Rheumatology (Oxford)
; 62(SI): SI54-SI63, 2023 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35731139
6.
CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization.
Rheumatology (Oxford)
; 62(10): 3433-3438, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37079727
7.
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.
Rheumatology (Oxford)
; 62(5): 1877-1886, 2023 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36173318
8.
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Respir Res
; 24(1): 6, 2023 Jan 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36624431
9.
Long-term evaluation of pulmonary function and survival of patients with interstitial pneumonia with autoimmune features.
Clin Exp Rheumatol
; 41(1): 15-23, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35383557
10.
The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.
Clin Exp Rheumatol
; 41(8): 1632-1638, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37497718
11.
HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry.
Proc Natl Acad Sci U S A
; 117(1): 552-562, 2020 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31871193
12.
Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry.
Rheumatology (Oxford)
; 61(4): 1510-1517, 2022 04 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34273167
13.
A Novel Utility to Correct for Plate/Batch/Lot and Nonspecific Binding Artifacts in Luminex Data.
J Immunol
; 204(12): 3425-3433, 2020 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32376648
14.
Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design.
Rheumatology (Oxford)
; 60(10): 4662-4670, 2021 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33506859
15.
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
Ann Rheum Dis
; 79(5): 618-625, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32299845
16.
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.
Ann Rheum Dis
; 79(3): 379-386, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31767698
17.
Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials.
Clin Exp Rheumatol
; 38 Suppl 125(3): 161-168, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32865169
18.
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Ann Rheum Dis
; 78(1): 122-130, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30409830
19.
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
Ann Rheum Dis
; 77(2): 212-220, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29066464
20.
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
Rheumatology (Oxford)
; 57(1): 152-157, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29077900